DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference.

GlobeNewsWire • 13 hours ago

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.

GlobeNewsWire • Jun 8, 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.

GlobeNewsWire • Jun 5, 2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the “Board”).

GlobeNewsWire • Jun 3, 2026

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy First participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, Ontario DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months in achieving ad lib consumption of dietary peanut. “Recent studies such as the LEAP trial, suggest there is a critical period, or ‘window of opportunity', in food allergy treatment during which early interventions may influence the trajectory of the allergy, its management, and long-term outcomes,” said Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University and a principal investigator of THRIVE, “Given the higher immune plasticity associated with younger patients, we are very pleased this first-of-its kind study assessing the efficacy and safety of the VIASKIN ® Peanut Patch in this very young population is now underway.

GlobeNewsWire • Jun 2, 2026

Combined General Meeting of June 3, 2026

Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 3, 2026, at 10:00 a.m. CEST (04:00 a.m.

GlobeNewsWire • May 13, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C.

GlobeNewsWire • May 12, 2026

DBV Technologies Reports First Quarter 2026 Financial Results

Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement (“PIPE”) financing Continued disciplined execution focused on BLA filing in the first half of this year and commercial preparedness for the U.S. launch of the VIASKIN® Peanut Patch for children aged 4 to 7 years, if approved DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today reported financial results for the first quarter of 2026. The quarterly and three months unaudited condensed financial statements were approved by the Board of Directors on April 30, 2026.

GlobeNewsWire • Apr 30, 2026

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

Zacks Investment Research • Apr 24, 2026

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies S.A. (DBVT) reported positive Phase 3 VITESSE results for Viaskin Peanut, advancing toward blockbuster sales projections exceeding $2 billion. My model estimates Viaskin Peanut's U.S. peak sales at $1.25 billion, with global revenues potentially reaching $2.1 billion, assuming central penetration and duration metrics. Current DBVT market valuation (~$2 billion) implies either lower peak sales or higher perceived risk versus a risk-adjusted valuation near $5 billion.

Seeking Alpha • Apr 17, 2026